DOCETAXEL IN THE FIRST-LINE TREATMENT OF NON-SMALL-CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS VERSUS VINORELBINE FROM THE TAX 326 TRIAL

被引：0
|
作者：
Baillot, S. [1 ]
de Pouvourville, G. [2 ]
Morais, E. [3 ]
Scharzinger, M. [1 ]
Fossella, F. [4 ]
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] ESSEC, Chaire Sante, Cergy Pontoise, France
[3] Sanofi Aventis R&D, Hlth Econ & Reimbursement, Paris, France
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：227 / 227
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer
    Aguilar-Serra, J.
    Gimeno-Ballester, V
    Pastor-Clerigues, A.
    Milara, J.
    Trigo-Vicente, C.
    Cortijo, J.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (04) : 637 - 646
  • [42] Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer
    Georgieva, M.
    Aguiar, P., Jr.
    Lima, J. P.
    Haaland, B.
    Lopes, G.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2148 - S2149
  • [43] COST-EFFECTIVENESS OF FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Yang, M. C.
    Tan, E. C. H.
    VALUE IN HEALTH, 2014, 17 (07) : A736 - A736
  • [44] Docetaxel Versus Vinorelbine in Elderly Patients With Advanced Non-Small-Cell Lung Cancer
    Karampeazis, Athanasios
    Georgoulias, Vassilis
    CLINICAL LUNG CANCER, 2012, 13 (05) : 397 - 397
  • [45] First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China
    Li, Ling-Yu
    Wang, Hong
    Chen, Xiao
    Li, Wen-Qian
    Cui, Jiu-Wei
    CHINESE MEDICAL JOURNAL, 2019, 132 (23) : 2790 - 2794
  • [46] Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China
    You, Ruxu
    Liu, Jinyu
    Wu, David Bin-Chia
    Qian, XinYu
    Lyu, Boxiang
    Zhang, Yu
    Luo, Nan
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 10239 - 10248
  • [47] COST-EFFECTIVENESS ANALYSIS OF TREMELIMUMAB AS FIRST-LINE THERAPY FOR METASTATIC NON-SMALL CELL LUNG CANCER IN JAPAN
    Sakai, R.
    Moriwaki, K.
    Morimoto, K.
    Shimozuma, K.
    VALUE IN HEALTH, 2024, 27 (06) : S150 - S150
  • [48] Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial
    Xiang, Heng
    Meng, Kehui
    Wu, Meiyu
    Tan, Chongqing
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (08) : 1043 - 1051
  • [49] Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
    Zhang, Longfeng
    Li, Na
    Liu, Maobai
    Zheng, Bin
    Wu, Zhijuan
    Cai, Hongfu
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 4263 - 4270
  • [50] Cost-effectiveness of chemotherapy in non-small-cell lung cancer
    Saglam, S
    Yetis, B
    Ozyilkan, O
    Akçali, Z
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) : 3750 - 3751
12345